{"nctId":"NCT02466087","briefTitle":"Role of Magnesium Supplementation in the Treatment of Depression","startDateStruct":{"date":"2015-05","type":"ACTUAL"},"conditions":["Depression"],"count":126,"armGroups":[{"label":"Mg Cl","type":"EXPERIMENTAL","interventionNames":["Drug: Mg Cl"]},{"label":"Control","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Mg Cl","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All adults at least 18 years of age\n* A Patient Health Questionnaire-9 (PHQ-9) score of greater or equal to 5 but less than 20\n* People who are currently being treated for depression are still eligible to participate but their treatment must be stable (no changes in medication dose or brand and/or no changes in therapy regimen for at least 2 months).\n\nExclusion Criteria:\n\n* Active delirium or dementia\n* Medicinal treatment for bipolar disorder, personality disorder or schizophrenia,\n* Glomerular Filtration Rate of less than 60\n* Irritable Bowel Disease\n* Inflammatory Bowel Disease\n* GERD\n* Gastritis\n* Pregnant as reported by potential volunteer\n* Myasthenia Gravis\n* Planned elective surgery\n* Currently taking\n\n  * Long Term Antibiotics\n  * Fluoroquinolone\n  * Trientine or Penicillamine\n  * Long Term Antivirals\n  * Digoxin\n  * Bisphosphonates\n  * Eltrombopag\n  * Opiods\n  * Calcium Channel Blockers\n  * Deferiprone\n  * Doxercalciferol\n* Unable or unwilling to stop taking a magnesium supplement","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Health Questionnaire-9","description":"Change in score from week 1 to week 6 and week 7 to week 12 (difference in differences)\n\nThe Patient Health Questionnaire-9 Item is a validated questionnaire with high sensitivity and specificity for the diagnosis of depression. The PHQ-9 score can range from 0 to 27, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-19 Moderate to Severe; 20-27 Severe.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.28","spread":null},{"groupId":"OG001","value":"-0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Generalized Anxiety Disorder 7 Item Questionnaire","description":"Change in score from week 1 to week 6 and week 7 to 12 (difference in differences)\n\nGAD-7 score has been shown to be a valid indication of anxiety symptoms. The GAD-7 score can range from 0 to 21, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-21 Severe.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.88","spread":null},{"groupId":"OG001","value":"0.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Headaches While Taking Supplements","description":"Change in headaches compared to normal during the 6 weeks on supplements. Change was calculated from 2 time points-start of supplements and end of supplements.\n\nChange was recorded as 0, None (same)\n\n1. Mild\n2. Moderate\n3. Severe (worse)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":null},{"groupId":"OG001","value":"-0.14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":62},"commonTop":[]}}}